Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tumor volume monitoring using circulating tumor DNA in unresectable hepatocellular carcinoma
jRCT1020200017Recruiting
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sorafenib and lenvatinib in hepatocellular carcinoma (HCC). Primary endpoint: Objective response rate at 2 months. Started Aug 2020; status: recruiting.
02
Drugs
sorafeniblenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT1020200017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1020200017.